Home > Statements & Submissions
Statements & Submissions
Statements & Submissions
FEB 17
BIOTECanada welcomes the launch of Canada’s Defence Industrial Strategy, and the recognition of life sciences as part of Canada’s broader security, innovation, and economic agenda by Prime Minister Mark Carney earlier today. The strategy’s emphasis on strengthening the generation and sovereign control of Canadian IP, securing supply chains, investing in defence and dual-use technologies, and ensuring a secure supply of Canadian-sourced medical countermeasures reinforces…
Read More
Statements & Submissions
DEC 3
BIOTECanada welcomes the launch of CanReview, a pan-Canadian initiative supported by the Accelerating Clinical Trials (ACT) Consortium, as a major step forward for Canada’s life sciences ecosystem. By replacing multiple provincial ethics reviews with a single, national process, CanReview is breaking down interprovincial barriers, speeding up clinical trial start-up, and making Canada more competitive on…
Read More
Statements & Submissions
NOV 19
Through its latest proposals, BIOTECanada acknowledges and commends the pCPA’s efforts to accelerate timelines so that patients can access high-value medicines sooner. In support of this objective, BIOTECanada has shared the following member input on the pCPA’s proposed Early Negotiation Process (ENP) and Targeted Negotiation Process. We remain engaged and look forward to working with…
Read More
Statements & Submissions
SEP 30
BIOTECanada in collaboration with IMC submitted member input to Canada’s Drug Agency`s (CDA-AMC) consultation on the draft assessment framework intended to inform adoption or funding decisions on molecular, genetic, and genomic biomarker testing in cancer care. The submission highlighted clear opportunities to enhance system-wide preparedness for innovative diagnostic testing ensuring both improved health outcomes and greater equity in care,…
Read More
Statements & Submissions
AUG 12
Securing Canada’s Future in Life Sciences: A Strategic Imperative Amid Global Competition As evidenced by recent events, Canada stands at a critical inflection point. Generations of North American economic integration are being tested, and traditional sectors are under the direct challenge of sustainability. Amid this turbulence, one sector stands out for its resilience and transformative…
Read More
Statements & Submissions
AUG 6
The members of the National Biotech Accord released A Joint Call To Action For Canada’s Life Sciences Future. This letter, representing a unified message from all provincial signatories of the National Biotech Accord underscores a shared commitment to advancing Canada’s life sciences sector. The document sends a clear signal: Life sciences are essential to both Canada’s…
Read More
Statements & Submissions
AUG 1
Section 1: Feedback on Observations Observation Category 1: Establishing a Collaborative Environment Do you agree with the major current observations by the advisory panel in this category? No Canada currently lacks a structured, national forum for ongoing collaboration as well as centralized data sources across the pharmaceutical ecosystem. There are significant differences amongst the public…
Read More
Statements & Submissions
MAY 14
BIOTECanada congratulates the new members of the new Canadian Ministry and looks forward to working collaboratively with the Government of Canada to support the continued growth of Canada’s biotechnology sector. As global competition intensifies, biotechnology stands as a strategic national asset, contributing to improved health outcomes, economic growth, and long-term resilience. Canada's research excellence, skilled…
Read More
Statements & Submissions
APR 29
BIOTECanada congratulates Prime Minister Mark Carney and his new government on their election victory. At a time of global economic uncertainty and shifting geopolitical dynamics, this mandate presents a critical opportunity for the Prime Minister and his team to strengthen Canada’s position as a global leader in life sciences and biotechnology, and build long-term economic…
Read More
Statements & Submissions
MAR 28
March 28, 2025 The Honourable François-Philippe Champagne, P.C., M.P. Minister of FinanceThe Honourable Anita Anand, P.C., M.P. Minister of Innovation, Science and IndustryThe Honourable Kamal Khera, P.C., M.P. Minister of HealthHouse of CommonsOttawa, ON K1A 0A6 Dear Ministers, On behalf of the members of the National Biotech Accord, which represent Canada’s biotechnology and life sciences…
Read More
Statements & Submissions
MAR 26
BIOTECanada celebrates the bilateral agreement between the Government of Canada and the province of Quebec, completing a pan-Canadian commitment to the national strategy for drugs for rare diseases. This milestone marks a united effort across all provinces and territories to improve access to new solutions for Canadian rare disease patients. From early stage biotechs to…
Read More
Statements & Submissions
MAR 19
BIOTECanada has provided written feedback on the Patented Medicine Prices Review Board’s (PMPRB) Draft Guidelines to reinforce the need for stability, transparency, and predictability in Canada’s pricing framework. As the voice of Canada’s biotech industry, our recommendations focus on ensuring a competitive investment environment, regulatory clarity, and continued access to transformative therapies for patients. We…
Read More
MembershipJoin the voice of Canadian biotech
- A seat at the table in federal policy consultations
- Members-only insights, briefings, and the CEO Report
- Cost savings program with vetted industry suppliers
- Discounted access to BIONATION and Canada @ BIO
230+
- Health & pharmaceutical
- Agricultural biotechnology
- Industrial & environmental
- Emerging fields